

1 **A novel whole-blood stimulation assay to detect and quantify memory T-cells in COVID-19 patients**

2 William Mouton^{1, 2, 3}, Christelle Compagnon^{1, 3}, Kahina Saker¹, Soizic Daniel⁴, Xavier Lacoux⁴, Bruno
3 Pozzetto⁵, Guy Oriol^{1, 3}, Sophia Djebali², Franck Berthier⁴, Jacqueline Marvel², Thierry Walzer², Karen
4 Brengel-Pesce^{1, 3*}, Sophie Trouiller-Assant^{1, 2*} on behalf of COVID-ser study group

5 ¹Joint Research Unit Hospices Civils de Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital,
6 Pierre-Bénite, France.

7 ²CIRI- International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, ENS
8 Lyon, Claude Bernard Lyon 1 University, Lyon, France.

9 ³Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France.

10 ⁴R&D – Immunoassay, bioMérieux S.A., Marcy l'Etoile, France.

11 ⁵GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Jean Monnet University,
12 Lyon University, Saint-Etienne, France; Laboratoire des Agents Infectieux et Hygiène, Saint-Etienne
13 Univesity hospital, Saint-Etienne, France.

14 *These authors share senior authorship.

15 **Corresponding author post-publication :**

16 Sophie Trouillet-Assant, PhD

17 Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux.

18 Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, France.

19 Tel: +33(0)4 72 67 87 81; Fax: +33(0)4 72 67 87 87

20 Email: Sophie.assant@chu-lyon.fr

21 **Keywords:** SARS-CoV-2 ; Immune functional assays ; T-cells response ; Immune memory

22 **Running title:** T-cells memory 6 months post COVID-19

23 **Abstract**

24 SARS-CoV-2 specific T-cells responses are essential for virus clearance. We present a novel and
25 simple whole-blood assay allowing the detection of interferon-gamma-producing antiviral T-cells
26 following peptide stimulation. We show that unlike neutralizing antibodies, antiviral memory T-cells
27 persist at least 6 months in convalescent Covid-19 individuals.

28 **Introduction**

29 As our understanding of the immune response against SARS-CoV-2 improves, it becomes clear that
30 virus-specific T-cells are key players in the control of infection and that suboptimal T-cells response
31 likely explains Covid-19 severity in many individuals [1]. SARS-CoV-2 specific T-cells responses often
32 target epitopes conserved in different virus clades, including variants of concern [2], and even in
33 other seasonal human coronaviruses (HCoV) [3]. Thus, memory T-cells may be more cross-protective
34 than antibodies against different coronavirus infections. In addition, specific SARS-CoV-2 T-cells
35 responses have been detected in convalescent donors without antibody responses [3] suggesting
36 that, at least in some individuals, the measurement of T-cells responses may outperform serological
37 measurements to uncover past infections. Thus, novel immunodiagnostics that measure cellular
38 immune response to SARS-CoV-2 are needed to assess individual immune status and evaluate
39 emerging vaccines in a robust and standardized manner, adapted to the clinical routine.

40 For this purpose, we designed a novel semi-automated whole-blood immune functional assay (WB
41 IFA) to detect and quantify SARS-CoV-2-specific T-cells immunity. WB assays are rapid and simple
42 assays that preserve all interactions between circulating immune cells, which likely reflects the *in*
43 *vivo* situation [4]. Interferon-gamma (IFN γ) secretion measurement following WB SARS-CoV-2
44 peptides stimulation was used to reveal SARS-CoV-2 specific T-cells, as previously described [5].

45 Using the IFA, we monitored T-cells immunity directed against different SARS-CoV-2 proteins
46 including nucleocapsid (NC), membrane glycoprotein (MBGP) and receptor-binding domain (RBD) in a
47 cohort of 129 Covid-19 convalescent healthcare workers (HCWs) previously infected 6 months before

48 with SARS-CoV-2. We correlated these measurements with serological levels of antibodies (Abs)
49 against SARS-CoV-2. We also assessed the specificity of the IFA assay for SARS-CoV-2 by performing
50 measurements in 25 SARS-CoV-2 seronegative healthy volunteers (HV) and in 3 HCWs having
51 experienced a previous documented infection by HCoV.

52 **Methods**

53 **Study design**

54 A prospective cohort study was conducted at the Hospices Civils de Lyon, France in HCWs with
55 symptoms suggestive of SARS-CoV-2 infection. The clinical study was registered on ClinicalTrial.gov
56 (NCT04341142) [6]. Written informed consent was obtained from participants and the study was
57 approved by the national review board for biomedical research (Comité de Protection des Personnes
58 Sud Méditerranée, ID-RCB-2020-A00932-37). Nasopharyngeal swabs collected at inclusion were
59 tested with the BIOFIRE® Respiratory Panel (bioMérieux,). At 6 months post-infection, blood
60 sampling was performed on 129 HCWs who were SARS-CoV-2 positive and 3 HCWs who were HKU-1
61 or NL-63 positive. According to French procedures, a written non-opposition to the use of donated
62 blood for research purposes was obtained from HV. The donors' personal data were anonymized
63 before transfer to our research laboratory. We obtained approval from the local ethical committee
64 and the French ministry of research (DC-2008-64) for handling and conservation of these samples.

65 **Serological investigations**

66 The presence of anti-SARS CoV-2 Ab was evaluated on serum samples using the Wantai Ab assay that
67 measures total Abs against the RBD of the S protein and the bioMérieux Vidas® assay that measures
68 IgG to the RBD. Positivity was established according to the threshold value recommended by each
69 manufacturer. The neutralizing antibody (NAb) titres were determined by a virus neutralization test
70 (VNT) using live SARS-CoV-2 virus as previously described [7].

71 **T-cells response after WB stimulation against SARS-CoV-2 peptides**

72 Fresh blood collected in heparanized tubes was stimulated for 22 hours at 37°C under 5% of CO₂ with
73 peptide pools targeting RBD (46 peptides), MBGP (53 peptides) or NC (102 peptides) (bioMérieux,
74 France) diluted in IFA solution (bioMérieux, France). The IFA solution was used as a negative control
75 and a mitogen as a positive control. The peptides (15-mer) encompassed the whole protein sequence
76 and overlapped by 5-residues. The concentration of IFN γ in the supernatant was measured using the
77 VIDAS automated platform (VIDAS® IFN γ RUO, bioMérieux). The measuring range was 0.08 -8 IU/mL
78 and IFA positivity thresholds were defined at 0.08 IU/mL. The IFN γ response was defined as positive
79 when the IFN γ concentration of the test was above threshold and the negative control was below
80 threshold or when the IFN γ concentration of the test minus IFN γ concentration of the negative
81 control was above threshold. All positive controls were \geq 8 IU/mL.

82 **Statistical analysis**

83 For T-cells responses, comparisons were performed using non-parametric Kruskal-Wallis test and
84 Dunn's multiple comparisons test; the overall, positive and negative percent agreements were
85 determined between T-cells response and serological assays or VNT as previously described [8].
86 Statistical analyses were conducted using GraphPad Prism® software (GraphPad software, La Jolla,
87 USA) and R software. A p-value \leq 0.05 was considered as statistically significant.

88 **Results**

89 We first monitored SARS-CoV-2 specific Abs using the Wantai total Ab kit in the three different
90 groups of participants (HV, or convalescent HCWs with previous infection by SARS-CoV-2 or HCoV
91 occurring 6 months before). These Abs were undetectable in the sera from the 3 HCoV positive HCWs
92 and from the 25 HV, confirming the absence of SARS-CoV-2 previous infection. By contrast, they
93 were detected in all 129 HCWs with documented SARS-CoV-2 infection 6 months before. Among

94 them, we observed that 82.9% (n=107) were positive for IgG anti-SARS-CoV-2 RBD detection
95 (bioMérieux VIDAS) and that only 48.8% (n=63) had neutralizing Abs (Nabs, Supplementary Table 1).

96 We then monitored the T-cells response against MBGP, RBD and NC peptides using the IFA WB assay
97 for the different patients' groups. A positive IFN γ release was detected for 89.1% (n=115/129;
98 median 0.51 [0.24-1.49] IU/mL), 62.4% (n=58/93; median 0.12 [0.17-0.34] IU/mL) and 97.9%
99 (n=92/94; median 1.20 [0.60-2.48] IU/mL) of SARS-CoV-2 positive HCWs after stimulation with MBGP
100 (Figure 1A), RBD (Figure 1B) and NC (Figure 1C) SARS-CoV-2 peptides respectively. No or very low
101 IFN γ release (<0.12 IU/mL) was detected for HV and HCoV upon stimulation with MBGP or RBD
102 (Figure 1A et 1B). Interestingly, two of the three HCoV positive HCWs (0.45 [0.10-0.79] IU/mL), as
103 well as 44% (n=11/25, 0.20 [0.13-0.32] IU/mL) of the HV showed a positive IFN γ response upon
104 stimulation with NC (Figure 1C), confirming that HCoV-specific T-cells cross-reacted with some of the
105 SARS-CoV-2 NC peptides that were used [9].

106 The overall percent agreement between T-cells responses against MBGP or RBD IFA and positive IgG
107 anti-SARS-CoV-2 RBD (BioMérieux IgG assay) was of 78.29% and 70.97% respectively. Among the 22
108 Covid-19 convalescent HCWs with undetectable anti-SARS-CoV-2-RBD IgG, only 4 did not have MBGP-
109 specific T-cells, which resulted in a low negative percent agreement between cellular and humoral
110 responses (18.18%). Moreover, among the 66 convalescent HCWs who lacked neutralizing Abs at 6
111 months post-infection, 81.8% (n=54) had MBGP-specific T-cells (detailed in supplementary Table 1).
112 These results suggest that, in the case of undetectable nAbs against SARS-CoV-2, a T-cells response
113 can still be observed.

114 **Concluding remarks**

115 Here, we presented a novel WB IFA assay that is highly efficient in detecting SARS-CoV-2 specific T-
116 cells responses, especially those directed against MBGP. IFN γ -release quantification following WB
117 stimulation could thus be proposed as a suitable and rapid option for assessing the presence of a
118 long-term specific cellular response after natural SARS-CoV-2 infection.

119 In our cohort of Covid-19 convalescent HCWs, we observed that about 90% of patients had a
120 detectable T-cells response after SARS-CoV-2 peptide stimulation at 6 months post symptoms, in
121 accordance with recent results [10]. Thus, our results suggest that WB IFA stimulation assays can be
122 used to detect memory T-cells in convalescent patients, even at late phases post infection, extending
123 previous findings by *Murugesan et al.* [5] who used a similar approach in recently-infected patients
124 by SARS-CoV-2. Moreover, we confirmed that IFN γ secretion was a robust read-out to assess SARS-
125 CoV-2 memory T-cells responses over time [11]. Yet, peptides derived from distinct viral proteins
126 showed a different capacity to trigger a T-cells response in patients. The highest positivity was
127 observed after stimulation with NC peptides. These peptides could even induce IFN γ secretion by
128 HCoV-convalescent HCWs and HV T-cells, suggesting cross-reactivity between seasonal HCoV and
129 SARS-CoV-2 and potential pre-existing immunity in HV, as previously described [9,12,13]. This also
130 suggests that stimulation using NC peptides encompassing the whole NC protein should not be used
131 as a specific diagnostic tool of SARS-CoV-2 immunity. By contrast, MBGP peptides seem to be more
132 appropriate to reveal SARS-CoV-2 specific memory T-cells. We also confirmed previous findings
133 regarding the relative short half-life of NAb and anti-SARS-CoV-2 IgGs [7]. Thus the measurement of
134 T-cells responses may outperform serological measurements to uncover past infections.

135 We acknowledge that our study has some limitations: (i) the WB IFA assay was not able to
136 differentiate between CD8+ and CD4+ T-cells responses, (ii) it does not determine whether memory
137 T-cells are protective against SARS-CoV-2 re-infection and (iii) it was not yet evaluated in vaccinated
138 subjects.

139 **Funding**

140 This work was supported by bioMérieux SA which provided kits for this study. This research is being
141 supported by Hospices Civils de Lyon and by Fondation des Hospices Civils de Lyon.

142 **Acknowledgments**

143 We thank all the personnel of the occupational health and medicine department of Hospices Civils de
144 Lyon who contributed to the samples collection. We thank Karima Brahami and all members of the
145 clinical research and innovation department for their reactivity (DRCI, Hospices Civils de Lyon). A
146 special thanks to Virginie Pitiot and PMO team for their help in patient enrolment and clinical data
147 collection.

148 *Potential conflicts of interest:* WM, CC, SD, XL, GO, FB and KBP, are employed in bioMérieux SA,
149 an *in vitro* diagnostic company.

150 *No conflict of interest:* KS, BP, SD, JM, TW and STA

151

152 **Reference**

- 153 1. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* **2021**; 184:861–880.
- 154 2. Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Vaccine-induced immunity provides more
155 robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of
156 concern. In Review, 2021. Available at: <https://www.researchsquare.com/article/rs-226857/v1>.
157 Accessed 8 March 2021.
- 158 3. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and
159 COVID-19-induced T cell recognition. *Nat Immunol* **2021**; 22:74–85.
- 160 4. Albert-Vega C, Tawfik DM, Trouillet-Assant S, Vachot L, Mallet F, Textoris J. Immune Functional
161 Assays, From Custom to Standardized Tests for Precision Medicine. *Front Immunol* **2018**;
162 9:2367.
- 163 5. Murugesan K, Jagannathan P, Pham TD, et al. Interferon-gamma release assay for accurate
164 detection of SARS-CoV-2 T cell response. *Clinical Infectious Diseases* **2020**; :ciaa1537.
- 165 6. Trouillet-Assant S, Albert Vega C, Bal A, et al. Assessment of serological techniques for
166 screening patients for COVID-19 (COVID-SER): a prospective, multicentric study. *BMJ Open*
167 **2020**; 10:e041268.
- 168 7. Bal A, Traubad M-A, Fassier J-B, et al. Six-month antibody response to SARS-CoV-2 in healthcare
169 workers assessed by virus neutralisation and commercial assays. *Infectious Diseases (except*
170 *HIV/AIDS)*, 2020. Available at: <http://medrxiv.org/lookup/doi/10.1101/2020.12.08.20245811>.
171 Accessed 19 February 2021.
- 172 8. Obermeier P, Muehlhans S, Hoppe C, et al. Enabling Precision Medicine With Digital Case
173 Classification at the Point-of-Care. *EBioMedicine* **2016**; 4:191–196.
- 174 9. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and
175 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Rep Med* **2021**; 2:100204.
- 176 10. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8
177 months after infection. *Science* **2021**; 371:eabf4063.
- 178 11. Pérez-Cabezas B, Ribeiro R, Costa I, et al. IL-2 and IFN- γ are biomarkers of SARS-CoV-2 specific
179 cellular response in whole blood stimulation assays. *Infectious Diseases (except HIV/AIDS)*,
180 2021. Available at: <http://medrxiv.org/lookup/doi/10.1101/2021.01.04.20248897>. Accessed 18
181 February 2021.
- 182 12. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus
183 in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **2020**; 181:1489-1501.e15.
- 184 13. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in
185 unexposed humans. *Science* **2020**; 370:89–94.

186




A. MBGP peptides stimulation**B. RBD peptides stimulation****C. NC peptides stimulation**

Figure legend

Figure 1: IFN γ release after *in vitro* WB stimulation using SARS-CoV-2 peptide pools. IFN γ levels in WB samples from 129 SARS-CoV-2 convalescent HCWs (dot), 3 HCoV convalescent HCWs (square) and 25 controls (HV) (triangle). IFN γ secretion was measured after a 22-hour stimulation using **(A)** MBGP peptides, **(B)** RBD peptides and **(C)** NC peptides. Statistical differences were inferred using non-parametric Kruskal-Wallis test and Dunn's multiple comparisons test.

Abbreviations: HCoV: seasonal human coronaviruses; HCWs: healthcare workers; HV: healthy volunteers; IU: international unit; MBGP: membrane glycoprotein; NC: nucleocapsid; RBD: receptor binding domain.